Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide: A Multicenter, Prospective, Randomized Controlled Trial (IIT)

NCT07713992 is registered in ClinicalTrials.gov with Tianjin Medical University as lead sponsor.

NCT NCT07713992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07713992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide: A Multicenter, Prospective, Randomized Controlled Trial (IIT)
Lead sponsor
Tianjin Medical University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 15, 2026
Completion date
February 1, 2028
Enrollment
72 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic fatty liver disease (nafld) with history of diabetes melitus, type 2 diabetes mellitus (t2dm)